TLSI insider filings
TriSalus Life Sciences, Inc. — 50 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2026-11-19. Screen TLSI transaction legs live →
Insider transaction summary — last 90 days
2026-08-23 to 2026-11-21, from the filings listed below: 8 insider filings (Forms 3/4/5). Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 4 legs across 3 filings by 3 insiders — 125,192 shares, $294,205 total (shares × price as filed).
- Open-market sales (code S, non-derivative): 4 legs across 4 filings by 3 insiders — 1,481 shares, $5,435 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 1.
- Largest priced transaction: purchase of 50,000 shares @ $2.24 ($112,000) by Wahlstrom Mats, filed 2026-11-16.
By insider — same window
Open-market purchase/sale legs on non-derivative securities, grouped by the filing's reporting owner(s); joint filings appear once. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Insider | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|
| Szela Mary T — CEO and President, Director | 2 | 2 legs · 65,192 sh · $160,205 | — | 1 |
| Wahlstrom Mats — Director | 1 | 1 leg · 50,000 sh · $112,000 | — | — |
| Gordon Gary B. — Director | 1 | 1 leg · 10,000 sh · $22,000 | — | — |
| Marshak Richard — Chief Commercial Officer | 2 | — | 2 legs · 869 sh · $2,749 | — |
| Stevens Jennifer — Chief Regulatory Officer | 1 | — | 1 leg · 316 sh · $1,387 | — |
| Cox Bryan F. — Chief of Research | 1 | — | 1 leg · 296 sh · $1,299 | — |
Recent insider filings — TriSalus Life Sciences, Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-11-19 | 4 | Gordon Gary B. — Director | Purchase (P): 10,000 @ $2.20 | EDGAR |
| 2026-11-19 | 4 | Szela Mary T — CEO and President, Director | Purchase (P): 30,864 @ $2.31 · Purchase (P): 34,328 @ $2.59 | EDGAR |
| 2026-11-17 | 4 | Marshak Richard — Chief Commercial Officer | Sale (S): 544 @ $2.43 | EDGAR |
| 2026-11-16 | 4 | Wahlstrom Mats — Director | Purchase (P): 50,000 @ $2.24 | EDGAR |
| 2026-10-07 | 4 | Szela Mary T — CEO and President, Director | Tax withholding (F): 2,693 @ $4.38 | EDGAR |
| 2026-10-07 | 4 | Stevens Jennifer — Chief Regulatory Officer | Sale (S): 316 @ $4.39 | EDGAR |
| 2026-10-07 | 4 | Marshak Richard — Chief Commercial Officer | Sale (S): 325 @ $4.39 | EDGAR |
| 2026-10-07 | 4 | Cox Bryan F. — Chief of Research | Sale (S): 296 @ $4.39 | EDGAR |
| 2026-07-06 | 4 | Patience David — Chief Financial Officer | Tax withholding (F): 14,650 @ $4.46 | EDGAR |
| 2026-07-01 | 4 | Marshak Richard — Chief Commercial Officer | Grant/award (A): 561 @ $3.87 | EDGAR |
| 2026-07-01 | 4 | Szela Mary T — CEO and President, Director | Grant/award (A): 3,990 @ $3.87 | EDGAR |
| 2026-06-29 | 4 | Marshall Richard Henry — Chief Medical Officer | Grant/award (A): 60,000 @ $0 · Grant/award (A): 120,000 (derivative) @ $0 | EDGAR |
| 2026-05-19 | 4 | Marshak Richard — Chief Commercial Officer | Sale (S): 543 @ $2.67 | EDGAR |
| 2026-05-18 | 4 | Patience David — Chief Financial Officer | Purchase (P): 7,100 @ $2.43 | EDGAR |
| 2026-05-18 | 4 | Gordon Gary B. — Director | Purchase (P): 10,000 @ $2.46 | EDGAR |
| 2026-05-18 | 4 | Wahlstrom Mats — Director | Purchase (P): 60,000 @ $2.53 | EDGAR |
| 2026-05-18 | 4 | Stansky Michael P — Director | Purchase (P): 410,000 @ $2.50 · Purchase (P): 200,000 @ $2.50 | EDGAR |
| 2026-05-18 | 4 | Szela Mary T — CEO and President, Director | Purchase (P): 39,682 @ $2.59 | EDGAR |
| 2026-05-15 | 4 | Valle William — Director | Grant/award (A): 28,201 @ $0 · Grant/award (A): 24,553 @ $0 · Grant/award (A): 56,403 (derivative) @ $0 | EDGAR |
| 2026-05-15 | 4 | Gordon Gary B. — Director | Grant/award (A): 28,201 @ $0 · Grant/award (A): 24,553 @ $0 · Grant/award (A): 56,403 (derivative) @ $0 | EDGAR |
| 2026-05-15 | 4 | Wahlstrom Mats — Director | Grant/award (A): 37,602 @ $0 · Grant/award (A): 34,226 @ $0 · Grant/award (A): 75,204 (derivative) @ $0 | EDGAR |
| 2026-05-15 | 4 | Stansky Michael P — Director | Grant/award (A): 23,501 @ $0 · Grant/award (A): 20,089 @ $0 · Grant/award (A): 47,003 (derivative) @ $0 | EDGAR |
| 2026-05-15 | 4 | MATLIN DAVID J — Director | Grant/award (A): 28,201 @ $0 · Grant/award (A): 23,065 @ $0 · Grant/award (A): 56,403 (derivative) @ $0 | EDGAR |
| 2026-05-15 | 4 | HICKS KERRY R — Director | Grant/award (A): 28,201 @ $0 · Grant/award (A): 56,403 (derivative) @ $0 | EDGAR |
| 2026-04-20 | 4 | Frankenius Equity AB — 10% owner | Conversion (C): 759,000 @ $0 · Conversion (C): 230,000 (derivative) @ $0 | EDGAR |
| 2026-04-01 | 4 | MATLIN DAVID J — Director | Conversion (C): 330,000 @ $0 · Conversion (C): 100,000 (derivative) @ $0 | EDGAR |
| 2026-03-20 | 4 | Devlin Jodi — Chief of Clinical Operations | Sale (S): 1,162 @ $4.13 · Sale (S): 1,772 @ $4.09 · Sale (S): 273 @ $4.12 | EDGAR |
| 2026-03-20 | 4 | Cox Bryan F. — Chief of Research | Sale (S): 1,138 @ $4.13 · Sale (S): 1,467 @ $4.09 · Sale (S): 579 @ $4.12 | EDGAR |
| 2026-03-20 | 4 | Marshak Richard — Chief Commercial Officer | Sale (S): 1,449 @ $4.13 · Sale (S): 1,589 @ $4.09 · Sale (S): 419 @ $4.12 | EDGAR |
| 2026-03-20 | 4 | Stevens Jennifer — Chief Regulatory Officer | Sale (S): 1,204 @ $4.13 · Sale (S): 1,552 @ $4.09 · Sale (S): 774 @ $4.12 | EDGAR |
| 2026-03-20 | 4 | Szela Mary T — CEO and President, Director | Sale (S): 4,358 @ $4.13 · Sale (S): 15,944 @ $3.85 | EDGAR |
| 2026-02-23 | 4 | Patience David — Chief Financial Officer | Purchase (P): 3,657 @ $4.10 | EDGAR |
| 2026-02-23 | 4 | Valle William — Director | Purchase (P): 30,487 @ $4.10 | EDGAR |
| 2026-02-23 | 4 | Gordon Gary B. — Director | Purchase (P): 9,756 @ $4.10 | EDGAR |
| 2026-02-23 | 4 | Stansky Michael P — Director | Purchase (P): 243,900 @ $4.10 · Purchase (P): 117,198 @ $4.10 | EDGAR |
| 2026-02-23 | 4 | Szela Mary T — CEO and President, Director | Purchase (P): 30,487 @ $4.10 | EDGAR |
| 2026-02-11 | 4 | Stansky Michael P — Director | Grant/award (A): 92,537 (derivative) @ $0 | EDGAR |
| 2025-11-25 | 4 | Devlin Jodi — Chief of Clinical Operations | Grant/award (A): 50,000 @ $0 · Grant/award (A): 100,000 (derivative) @ $0 | EDGAR |
| 2025-11-25 | 4 | Marshak Richard — Chief Commercial Officer | Grant/award (A): 60,000 @ $0 · Grant/award (A): 120,000 (derivative) @ $0 | EDGAR |
| 2025-11-25 | 4 | Stevens Jennifer — Chief Regulatory Officer | Grant/award (A): 50,000 @ $0 · Grant/award (A): 100,000 (derivative) @ $0 | EDGAR |
| 2025-11-25 | 4 | Cox Bryan F. — Chief of Research | Grant/award (A): 40,000 @ $0 · Grant/award (A): 80,000 (derivative) @ $0 | EDGAR |
| 2025-11-25 | 4 | Patience David — Chief Financial Officer | Grant/award (A): 65,000 @ $0 · Grant/award (A): 130,000 (derivative) @ $0 | EDGAR |
| 2025-11-25 | 4 | Szela Mary T — CEO and President, Director | Grant/award (A): 125,000 @ $0 · Grant/award (A): 125,000 @ $0 · Grant/award (A): 300,000 @ $0 · Grant/award (A): 250,000 (derivative) @ $0 | EDGAR |
| 2025-08-29 | 4 | Patience David — Chief Financial Officer | Grant/award (A): 248,899 (derivative) @ $0 | EDGAR |
| 2025-08-15 | 4 | Patience David — Chief Financial Officer | Grant/award (A): 200,000 @ $0 · Grant/award (A): 290,000 (derivative) @ $0 | EDGAR |
| 2025-06-27 | 4 | Gordon Gary B. — Director | Grant/award (A): 15,000 (derivative) @ $0 | EDGAR |
| 2025-06-27 | 4 | Murphy Sean — Director | Grant/award (A): 15,000 (derivative) @ $0 | EDGAR |
| 2025-06-27 | 4 | Wahlstrom Mats — Director | Grant/award (A): 15,000 (derivative) @ $0 | EDGAR |
| 2025-06-27 | 4 | MATLIN DAVID J — Director | Grant/award (A): 15,000 (derivative) @ $0 | EDGAR |
| 2025-06-27 | 4 | HICKS KERRY R — Director | Grant/award (A): 15,000 (derivative) @ $0 | EDGAR |
Recent 8-K events — TriSalus Life Sciences, Inc.
Items classified from EDGAR index headers. Browse recent 8-K filings market-wide, by item code →
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-11-10 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-09-22 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-06 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-14 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2026-05-12 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-04-29 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
| 2026-04-07 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-05 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-02-20 | 8-K | 1.01 — Entry into a Material Definitive Agreement 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-02-09 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=TLSI returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. Get a free API key → · API docs